06 Dec Biosimilars – a novel aspect of cost containment in Health Insurance – Dr Detloff Rump
Posted at 12:04h
in Uncategorized
Biosimilars - a novel aspect of cost containment in Health Insurance With the advent of personalised medicine, it became obvious that in many cases the cost of pharmaceutical therapy presents a serious challenge to health insurers – and often also to the insured individual. For instance...